ALR Technologies SG has signed a Letter of Intent (LOI) to acquire 100% of CGM Medical Technology Singapore and selected assets of CGM Medical Technology Shenzhen in a transaction valued at US$45 million.

• Transaction Structure: The proposed acquisition includes 200 million ALR Technologies ordinary shares, an earn-out promissory note of up to US$40 million, and up to US$5 million in cash for the Shenzhen assets.
• Manufacturing Expansion: Following completion, ALR Technologies plans to establish a continuous glucose monitoring (CGM) manufacturing facility in the Johor–Singapore Special Economic Zone (JS-SEZ) while expanding production capacity in Shenzhen.
• Strategic Objective: The acquisition is intended to strengthen ALR Technologies’ manufacturing capabilities and support the commercialisation of its veterinary and future human continuous glucose monitoring products.

This summary is based on a news report published by BioSpectrum Asia.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.